chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Fatigue, Headache
Clinical narrative: Fatigue; Chills; Headache; Diarrhea; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 01Apr2021 at 12:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergy from an unknown date. The patient had no known allergies to medications, food, or other products. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken within two weeks of vaccination but not within 3 days of the vaccine for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 14Mar2021 at 13:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 02Apr2021 at 08:00, the patient experienced fatigue, chills, headache and diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fatigue, chills, headache and diarrhea was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Headache, Pain in extremity
Clinical narrative: Chills; Right finger pain; Wrist pain; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 44-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730 7/21) via an unspecified route of administration in the left arm on 03Apr2021 at 10:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies to medications, food or other products. Concomitant medications included levocetirizine dihydrochloride (XYZAL), from an unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL 9266) via an unspecified route of administration in the left arm on 09Mar2021 at 13:15 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 21:00, the patient experienced chills, right finger pain, wrist pain and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of chills, right finger pain, wrist pain and headache were recovered on unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Joint stiffness, Motor dysfunction, Paraesthesia
Clinical narrative: Felt tight around right shoulder joint centered on 1st injection site; Right side of body didn't work correctly. Right leg and arm felt odd, muted sensation in right arm and leg not numb, tingling or pins and needles feeling; Lack of fine motor control in right fingers; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8727) via an unspecified route of administration in the arm left on 30Mar2021 at 12:00(at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included  borderline diabetes and body mass index (30BMI). Patient had no allergies to food, medications or other products. Concomitant medications included metformin (MANUFACTURER UNKNOWN), ascorbic acid, copper gluconate, zinc oxide, tocopheryl acid succinate, xantofyl, zeaxanthin (AREDS 2 VISUAL ADVANTAGE), cetirizine hydrochloride (ZYRTEC), cannabidiol (CBD OIL) and glucosamine (MANUFACTURER UNKNOWN) all for unknown indications from an unknown date. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6205) via an unspecified route of administration in the arm right on 09Mar2021 at 12:00(at the age of 61-year-old) as a single dose for COVID-19 immunisation Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 07:00 the patient experienced lack of fine motor control in right fingers and right leg and arm felt odd, muted sensation in right arm and left; not numb, tingling or pins and needles feeling. On 06Apr2021 the patient experienced tight around right should joint. He woke up 2nd day after the second dose, the right side of his body didn't work correctly. Lack of fine motor control in right fingers which got better during the day, almost 100% . He called  and doctor said  he has heard several cases like this and prescribed anti-inflammatory medications. Symptoms lessened each day and by 06Apr2021 he was  walking normally, right fingers regaining fine motor control but feel tight around right shoulder joint centered on 1st injection site. The event lack of motor control and tingling resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of tingling and lack of motor control and included treatment with (SULINDAC) 200mg twice daily. The clinical outcome of the event lack of motor control, tingling and feel tight around right shoulder was recovering.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Polymenorrhoea
Clinical narrative: Early menstrual cycle; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration in the right arm on 28Mar2021 at 09:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food or other products. The patient did not take any concomitant medications. The patient previously received first dose of BNT162b2 (COVID-19 Vaccine - Manufacturer Unknown; Lot Number: unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021, the patient experienced early menstrual cycle. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. The clinical outcome of early menstrual cycle was resolving at the time of this report.  No follow-up attempts are possible, information about batch number cannot be obtained.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenopia, Chills, Fatigue, Headache, Pain
Clinical narrative: soreness; body aches all over; headache; heavy eyes; pain at injection site; fatigue; chills; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the arm left on 02Apr2021 at 13:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to food, medications, or other products. The patient did not receive any other medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the arm left on 12Mar2021 at 13:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 21:00 the patient experienced soreness, body aches all over, headache, heavy eyes, pain at injection site, fatigue and chills. The patient did not receive any treatment for the events. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events soreness, body aches all over, headache, heavy eyes, pain at injection site, fatigue and chills were recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: soreness; body aches all over; headache; heavy eyes; pain at injection site; fatigue; chills; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the arm left on 02Apr2021 at 13:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to food, medications, or other products. The patient did not receive any other medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the arm left on 12Mar2021 at 13:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 21:00 the patient experienced soreness, body aches all over, headache, heavy eyes, pain at injection site, fatigue and chills. The patient did not receive any treatment for the events. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events soreness, body aches all over, headache, heavy eyes, pain at injection site, fatigue and chills were recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Oral herpes, Pain in extremity
Clinical narrative: resembling a cold sore in the right side corner of my mouth; sore arm; This is a spontaneous report from a contactable consumer or other non hcp (Patient, self-reporting). A patient of unspecified age and gender received BNT162B2 (BNT162B2, PFIZER-BIOTECH, COVID-19 VACCINE, Batch/Lot number was not reported), via an unspecified route of administration on 31Mar2021 as dose number unknown, single for COVID-19 immunization. Medical history included Vitamin B deficiency from an unknown date and unknown if ongoing. The patient concomitant medications were not reported. It was reported that patient received the Pfizer vaccine on Wednesday, 31Mar2021. initial physical reaction was a sore arm, subsequently had an additional reaction two days later that patient thought patient might pass along. On the evening of the next day, patient started developing something resembling a cold sore in the right side corner of patients mouth. This was something have had before, indicating a Vitamin B deficiency. As of today, Saturday 03Apr2021, patient have added supplements to remedy this. Therapeutic measures were taken as a result of events. The outcome for the events was reported as unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Lymphadenopathy, Neck pain
Clinical narrative: swollen lymph node under left arm; tiredness; dizzy; soreness in shoulders up neck and back of left side of head; soreness in shoulders up neck and back of left side of head; This is a spontaneous report from a non-contactable consumer, the patient. A 50-years-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 29Mar2021 at 10:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included Covid-19. The patient previously received cyclobenzaprine hydrochloride (FLEXERIL) on an unspecified date for an unknown indication and experienced drug allergy. Concomitant medications included allergy medicine from an unknown date for an unknown indication. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 29Mar2021 at 11:00, the patient experienced swollen lymph node under left arm, tiredness, dizzy, soreness in shoulders up neck and back of left side of head. No therapeutic measures were taken as the result of the reported adverse events. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events swollen lymph node under left arm, tiredness, dizzy, soreness in shoulders up neck and back of left side of head were resolving at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: SWOLLEN LYMPH NODES IN ARMPIT OF ARM THAT RECEIVED SHOT; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 11:15(at the age of 49-years-old) as a single dose for COVID-19 immunisation.  Medical history included blood pressure high. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and levothyroxine sodium (LEVOTHYROXIN),all from unknown dates and for unknown indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Mar2021 at 11:15(at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 04Apr2021 at 07:00, the patient experienced swollen lymph nodes in armpit(lymphadenopathy axillary) of arm that received the shot. The patient did not receive any treatment for the reported event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event swollen lymph nodes in armpit was not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Pharyngeal hypoaesthesia
Clinical narrative: 30 to 40 mins after injection an numbness creeped up my shoulder from the injection site; Numbed the left side of face and throat.; Numbed in left side of face and throat.; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6198) via an unspecified route of administration in the left arm on 17Mar2021 at 14:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity. The patient had no known allergies to medications, food, or other products. Concomitant medications included citalopram (MANUFACTURER UNKNOWN), naproxen (MANUFACTURER UNKNOWN), baclofen (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN); all taken for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 15:00, 30 to 40 minutes after vaccination, the patient experienced numbness creeped up her shoulder from the injection site, and numbed the left side of face and throat. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events numbness creeped up her shoulder from the injection site, and numbed the left side of face and throat was recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Diplopia, Hypersomnia, Pain in extremity
Clinical narrative: Double vision and couldn't focus; Slept for over 30 hours; Bad arm pain; This is a spontaneous report from a contactable consumer, the patient. A 21-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6208 6/21) via an unspecified route of administration in the left arm on 13Mar2021 at 15:00 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included bipolar 2, obsessive-compulsive disorder (OCD), anxiety, depression, sensory processing disorder and insomnia. The patient had no allergies to medications, food, or other products. Concomitant medications included doxepin (MANUFACTURER UNKNOWN), venlafaxine hydrochloride (EFFEXOR), gabapentin (MANUFACTURER UNKNOWN), eszopiclone (LUNESTA) started on an unknown date and was taking for close to an year with no issues for sleep, omeprazole (MANUFACTURER UNKNOWN) and patient had been on unspecified sleep medication for 7 years. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 14Mar2021, the patient had some bad arm pain. Starting on 15Mar2021 at 04:00 and also on 16Mar2021, the patient slept for over 30 hours and those were her days off. On 16Mar2021, when she did manage to stay awake for 6 hours she had double vision and could not focus. She had to take off on 17Mar2021 as well. The patient stated it was real worrying thing. On 30Mar2021, the patient slept for 18 straight hours, woke up showered and still felt asleep again after only being awake for 3 hours. No one seemed to have any information and the patient was pretty sure when she would go to sleep on the day of report at night, she would sleep for 20 hours again as that was her day off. The patient had never slept for more than 12 hours before. The patient stated that she had been on sleep medication for 7 years and eszopiclone cannot be blamed as she had no issues with it. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. The clinical outcome of the events bad pain in arm, slept for over 30 hours and double vision/couldn't focus were not resolved. No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Headache, Neck pain
Clinical narrative: surgeries and a neck fusion. The patient received unspecified concomitant medications within 2 weeks of vaccination. The patient had no allergies to medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on 12Mar2021 at 19:00 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 06:00, the patient experienced above moderate pain throughout her back and neck areas, specifically where she had a previous back surgery and the pain was much more significant in the areas where she had screws in the back. The back pain had lasted roughly for 48 hours. On 02Apr2021, the following day, the patient had headaches which had lasted a little over 48 hours. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events back pain was resolved on 03Apr2021 and of the neck pain and headaches was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Skin plaque
Clinical narrative: Scaly plaque type lesion on face about the diameter of a pea.; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 20:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included post concussion syndrome and cephalgia. The patient had allergies to food, medications, or other products (not specified). Concomitant medications included melatonin (MANUFACTURER UNKNOWN) started on an unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced scaly plaque type lesion on face about the diameter of a pea. The treatment received for the adverse event was not reported. The clinical outcome of the event scaly plaque type lesion on face was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Eye swelling, Vision blurred
Clinical narrative: Eyes swelled up; Vision blurry; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 13:00 (at the age of 19-year-old) as a single dose for COVID-19 immunisation. Medical history included obesity and asthma. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Mar2021 at 15:00 (at the age of 19-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 04Apr2021, the patient's eyes were swelled up and made his vision blurry. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events eyes swelled up and vision blurry were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Inflammation
Clinical narrative: R knee precious surgery 15 years ago now has tenderness; R knee precious surgery 15 years ago now has tenderness and inflammation.; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 28Mar2021 at 14:00 (at the age of 54-years-old), as a single dose for COVID-19 immunisation. Medical history included right knee surgery 15years ago, spontaneous coronary artery dissection (SCAD), fibromuscular dysplasia (FMD), hashimoto's disease and heart attack. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) of dose 88mcg, eplerenone (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN) and metoprolol (MANUFACTURER UNKNOWN), all from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW6204) via an unspecified route of administration in the right arm on 06Mar2021 at 11: 00 (at the age of 54-years-old), as a single dose for COVID-19 immunisation. The patient previously received oxycodone acetaminophen (PERCOCET) on an unknown date for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 01Apr2021 at 08:00, the patient had right knee precious surgery 15 years ago and now has tenderness and inflammation. Feels like it did prior to surgery. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events tenderness in right knee tenderness and inflammation was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Hyperhidrosis, Pain
Clinical narrative: 101 F fever; Aches; Headache; Chills; Sweats; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8730), via an unspecified route of administration in the right arm on 03Apr2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206), via an unspecified route of administration in the right arm on 12Mar2021 at 17:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 about 12 hours after the injection, the patient experienced a 101 degrees Fahrenheit fever, aches, headache, chills and sweats. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events experienced. The clinical outcome of the events 101 degrees Fahrenheit fever, aches, headache, chills and sweats was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: 101 F fever; Aches; Headache; Chills; Sweats; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8730), via an unspecified route of administration in the right arm on 03Apr2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206), via an unspecified route of administration in the right arm on 12Mar2021 at 17:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 about 12 hours after the injection, the patient experienced a 101 degrees Fahrenheit fever, aches, headache, chills and sweats. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events experienced. The clinical outcome of the events 101 degrees Fahrenheit fever, aches, headache, chills and sweats was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 12:00 hours (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included covid-19. Concomitant medications included kirkland aller-fex (MANUFACTURER UNKNOWN), glucosamine (MANUFACTURER UNKNOWN), both drugs started on an unknown date for unknown indication. Past medications were not reported. The patient had an allergy to contrast dye. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications or vaccines within four weeks prior to the vaccination. On 15Mar2021 at 12:50, the patient experienced the left side of the face went numb (numbness in the face). The patient took the vaccine at 12:00 hours and waited about 40 mins in the hospital. Then she noticed the left side of her face went numb about 10 mins after leaving the hospital. Lasted for 24 hours. The patient did not have any trouble breathing and did not seem like she needed to return. The patient did call hospital to notify of the reaction and also with the primary doctor office. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the event numbness in the face was recovered on 16Mar2021, after the duration of 24 hours.  No follow-up attempts are possible. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pollakiuria, Pyrexia
Clinical narrative: Urgent frequent urination; 100 degree fever; This is a spontaneous report received from a contactable consumer (patient) via COVID-19 Adverse Event Self-Reporting Solution. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 27Mar2021 at 14:00 (at the age of 59-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was not allergic to food, medication or any other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On 27Mar2021 at 14:00, the patient experienced urgent frequent urination. This was elaborated as sometimes so urgent, that was unable to make it to a bathroom, even at home. The patient also experienced 100-degree fever. Immediately upon receiving the shot, felt the need to urinate when there was no need to prior. On 27Mar2021 at 14:00, the patient underwent body temperature measurement and the result was 100-degree fever. The patient was not treated with any medication for the events. The adverse events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of urgent frequent urination and 100-degree fever was not resolved.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, Periorbital swelling
Clinical narrative: Eyelids got very puffy, as did under the eyes, want to shut eyes; Eye pain; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 13Mar2021 at 13:30 (at the age of 43-years-old) and also received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 13:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, anxiety and adrenal insufficiency. The patient did not have any allergies to medications, food, or other products. Concomitant medications included unspecified supplements for adrenal support and bupropion hydrochloride (WELLBUTRIN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in 2021, after first dose of vaccine, the patient felt eyelids got very puffy as it was under the eyes, it was making him want to shut his eyes and patient also had eye pain. On 03Apr2021 at 14:30, after second dose of vaccine, the patient again experienced the same events of puffy eyes and eye pain. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events eyelids got very puffy, as did under the eyes, want to shut eyes and eye pain was resolving at the time of this report.  No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, Swelling face
Clinical narrative: Head-to-toe itchy rash; Day after shot had swelling of face; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 16Mar2021 at 14:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies. The concomitant medication was taken by the patient (unspecified) within two weeks prior to COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 day after the shot, the patient experienced swelling of face and on 23Mar2021 by day seven, the patient experienced head-to-toe itchy rash. The events resulted in doctor or other healthcare professional office or clinic visit. Therapeutic measures were taken as a result of events which included treatment with prednisone oral and topical steroid cream from an unspecified date in 2021 and unknown if ongoing. The clinical outcome of the events head-to-toe itchy rash and swelling of face were recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Vaccination site pain
Clinical narrative: Achy joints; Fatigue; Pain at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 49-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 04Apr2021 at 11:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not provided. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration on unknown an date, as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced achy joints, fatigue and pain at injection site. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event's achy joints, fatigue and pain at injection site was not recovered.   No follow-up attempts are possible; No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Oropharyngeal pain, Pain, Pyrexia
Clinical narrative: Headache; Sore throat; Slight fever; Body ache, pain all over; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the arm left on 26Mar2021 at 16:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included amitriptyline (MANUFACTURER UNKNOWN) and birth control pills from an unspecified date. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 04:00, the patient experienced headache, sore throat, slight fever, joint pain and body ache, the worst part was the pain all over. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The patient did not receive any treatment for the events. The clinical outcome of the events headache, sore throat, slight fever, joint pain and body ache, the worst part was the pain all over was recovered on an unspecified date in 2021.  No follow-up attempts are needed. No further information is expected
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Eye pruritus, Eye swelling, Nasal crusting, Nasal inflammation, Nasal pruritus
Clinical narrative: Rash on arm, face, eyes.; Extreme itching; swollen eyes; Nose inflammation; Nose inflammation, itching and hardening; Nose inflammation, itching and hardening; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER 8733) via an unspecified route of administration in the left arm on 01Apr2021 at 12:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history were reported as none. The patient did not receive any medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 07:00, the patient experienced rash on arm, face, eyes, extreme itching and swollen eyes, nose inflammation, itching and hardening. The patient received treatment for the reported events which included Benadryl. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event rash on arm, face, eyes, extreme itching and swollen eyes, nose inflammation, itching and hardening was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash on arm, face, eyes.; Extreme itching; swollen eyes; Nose inflammation; Nose inflammation, itching and hardening; Nose inflammation, itching and hardening; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER 8733) via an unspecified route of administration in the left arm on 01Apr2021 at 12:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history were reported as none. The patient did not receive any medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 07:00, the patient experienced rash on arm, face, eyes, extreme itching and swollen eyes, nose inflammation, itching and hardening. The patient received treatment for the reported events which included Benadryl. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event rash on arm, face, eyes, extreme itching and swollen eyes, nose inflammation, itching and hardening was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: severe headache; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm left on 19Mar2021 at 11:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, osteoporosis and penicillin allergy. Concomitant medications included alendronate sodium (FOSAMAX) and sertraline hydrochloride (ZOLOFT). The patient previously took clindamycin and had an allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 the patient experienced a severe headache which was moderate to severe headaches continuing for more than two weeks after vaccination. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event severe headache was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache
Clinical narrative: Headache; Fatigue; Fogginess; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 05Apr2021 at 16:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and women's daily multivitamin (MANUFACTURER UNKNOWN); both taken for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 17:15, the patient experienced headache, fatigue and fogginess. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache, fatigue and fogginess was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.